This is an open multicenter trial. 152 out of 235 enrolled patients have already entered the database. Lamotrigine (LTG) was added on to an existing antiepileptic drug. 13 patients did not complete the 12 week treatment period because of poor compliance, protocol deviations, intercurrent illness or adverse reactions (2 skin rashes, 1 headache, 1 nausea and vomiting). One patient was excluded from the analysis on seizure frequency because of uncertain results. 71 patients (51,4%) out of 138 who completed the study experienced at least 50% reduction in total seizure frequency. LTG showed favorable effects on other subjective measurements (mood) and was well tolerated.
|Number of pages||5|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1994|
ASJC Scopus subject areas
- Clinical Neurology